ZA200600229B - Pyrrole-2,5-dithione derivatives as Liver X receptor modulators - Google Patents
Pyrrole-2,5-dithione derivatives as Liver X receptor modulatorsInfo
- Publication number
- ZA200600229B ZA200600229B ZA200600229A ZA200600229A ZA200600229B ZA 200600229 B ZA200600229 B ZA 200600229B ZA 200600229 A ZA200600229 A ZA 200600229A ZA 200600229 A ZA200600229 A ZA 200600229A ZA 200600229 B ZA200600229 B ZA 200600229B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrole
- liver
- receptor modulators
- dithione
- derivatives
- Prior art date
Links
- 102000004311 liver X receptors Human genes 0.000 title 1
- 108090000865 liver X receptors Proteins 0.000 title 1
- DVUZQONFTJKFPV-UHFFFAOYSA-N pyrrole-2,5-dithione Chemical class S=C1NC(=S)C=C1 DVUZQONFTJKFPV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600229B true ZA200600229B (en) | 2007-04-25 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600229A ZA200600229B (en) | 2003-07-11 | 2006-01-10 | Pyrrole-2,5-dithione derivatives as Liver X receptor modulators |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (https=) |
| EP (1) | EP1646625B1 (https=) |
| JP (1) | JP2007521313A (https=) |
| KR (1) | KR20060034284A (https=) |
| CN (1) | CN100478340C (https=) |
| AR (1) | AR045720A1 (https=) |
| AT (1) | ATE399776T1 (https=) |
| AU (1) | AU2004256000B2 (https=) |
| BR (1) | BRPI0412479A (https=) |
| CA (1) | CA2532068A1 (https=) |
| CO (1) | CO5640134A2 (https=) |
| DE (1) | DE602004014772D1 (https=) |
| ES (1) | ES2308205T3 (https=) |
| GB (1) | GB0316237D0 (https=) |
| IL (1) | IL172759A0 (https=) |
| IS (1) | IS8291A (https=) |
| MX (1) | MXPA06000447A (https=) |
| NO (1) | NO20060080L (https=) |
| RU (1) | RU2006102129A (https=) |
| SA (1) | SA04250203B1 (https=) |
| TW (1) | TW200507836A (https=) |
| UA (1) | UA82108C2 (https=) |
| UY (1) | UY28407A1 (https=) |
| WO (1) | WO2005005416A1 (https=) |
| ZA (1) | ZA200600229B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| CA2592771A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| US7989179B2 (en) * | 2005-06-28 | 2011-08-02 | Daiichi Sankyo Company, Limited | LXR ligand testing method |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| WO2008046014A1 (en) * | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| WO2008103818A1 (en) * | 2007-02-21 | 2008-08-28 | University Of Louisville Research Foundation | Therapeutic cotinine compositions |
| PT2868315T (pt) | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| US20110034560A1 (en) * | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| RU2509078C2 (ru) | 2008-07-01 | 2014-03-10 | Дженентек, Инк. | Бициклические гетероциклы в качестве ингибиторов киназы мек |
| MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE284387T1 (de) * | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en not_active Ceased
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Withdrawn
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en not_active Expired - Lifetime
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004256000A1 (en) | 2005-01-20 |
| EP1646625B1 (en) | 2008-07-02 |
| JP2007521313A (ja) | 2007-08-02 |
| KR20060034284A (ko) | 2006-04-21 |
| CN100478340C (zh) | 2009-04-15 |
| DE602004014772D1 (de) | 2008-08-14 |
| IL172759A0 (en) | 2006-04-10 |
| AU2004256000B2 (en) | 2007-07-26 |
| MXPA06000447A (es) | 2006-04-07 |
| CA2532068A1 (en) | 2005-01-20 |
| ES2308205T3 (es) | 2008-12-01 |
| US20060189663A1 (en) | 2006-08-24 |
| UA82108C2 (uk) | 2008-03-11 |
| GB0316237D0 (en) | 2003-08-13 |
| SA04250203B1 (ar) | 2008-02-25 |
| CO5640134A2 (es) | 2006-05-31 |
| RU2006102129A (ru) | 2006-08-27 |
| NO20060080L (no) | 2006-02-08 |
| UY28407A1 (es) | 2005-02-28 |
| CN1820003A (zh) | 2006-08-16 |
| EP1646625A1 (en) | 2006-04-19 |
| WO2005005416A1 (en) | 2005-01-20 |
| HK1088318A1 (en) | 2006-11-03 |
| AR045720A1 (es) | 2005-11-09 |
| BRPI0412479A (pt) | 2006-09-19 |
| IS8291A (is) | 2006-02-09 |
| ATE399776T1 (de) | 2008-07-15 |
| TW200507836A (en) | 2005-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL177218A0 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
| IL178767A0 (en) | Indolyl derivatives as liver - x - receptor modulators | |
| ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
| EP1773768B8 (en) | Pyrrole derivatives as pharmaceutical agents | |
| GB0400440D0 (en) | Receptor modulators | |
| EP1684762A4 (en) | UREA DERIVATIVES AS MODULATORS OF KINASE | |
| IL172759A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
| AU2003259482A1 (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators | |
| IL172760A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
| IL183140A0 (en) | Substituted benzoquinolizine derivatives | |
| IL182739A0 (en) | Acylatednonadepsipeptides used as lysobactin derivatives | |
| PL1638940T3 (pl) | Pochodne pirolidyniowe jako ligandy dla receptora muskarynowego M3 | |
| ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
| AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
| AP2501A (en) | Substituted pyrrole derivatives | |
| HK1112905A (en) | 5-thioxo-1,5-dihydro-2h-pyrrol-2-one derivatives as liver x receptor modulators | |
| ZA200606563B (en) | 3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators | |
| HK1095140A (en) | Pyrrolidine derivatives as cb1-receptor antagonists | |
| HK1084298A (zh) | 受体 | |
| GB0321998D0 (en) | Receptor | |
| AU2003904848A0 (en) | Receptor specific ligands | |
| HK1097253A (en) | Substituted hydroxyacetophenon derivatives | |
| IL173334A0 (en) | Thiazole derivatives as cannabinoid receptor modulators | |
| HK1106509A (en) | Pyrrolidine derivatives as muscarinic receptor antagonists | |
| HK1094968A (en) | Bazedoxifene ascorbate as selective estrogen receptor modulator |